The Stephan Beck Archive: Chronicles of Science, Safety, and Pharmaceutical History
We note over the years as a critical context for evaluating evidence and timelines.
Welcome to the Stephan Beck Archive, a living editorial resource founded on the conviction that understanding the past—especially the complex interplay of scientific discovery, regulatory oversight, and patient welfare—is essential for navigating today’s most pressing health challenges. Named in honor of the pioneering biochemist whose work on drug metabolism and toxicology laid the groundwork for modern pharmacovigilance, this site serves as a permanent, independent repository of meticulously researched articles, timelines, and reference materials. Our mission is to provide context, not advocacy; education, not litigation; and clarity, not confusion.
We are neither a law firm nor a medical practice. Instead, we are a team of science writers, historians, and data analysts who believe that the public deserves accessible, well-sourced information about landmark pharmaceutical controversies. In 2026, our focus remains on one of the most consequential drug-safety stories of the twenty-first century: the link between ranitidine (sold under the brand name Zantac) and the formation of the probable human carcinogen N-nitrosodimethylamine (NDMA). Readers will find here a comprehensive archive of scientific studies, regulatory chronologies, and case-evaluation guidance—all presented in plain language for patients, journalists, researchers, and legal professionals seeking authoritative context.
Comprehensive Reference Materials on Drug Safety Litigation
Our reference library includes detailed dossiers on the chemistry of NDMA, the metabolism of ranitidine, and the epidemiological evidence that prompted global recalls. We trace the evolution of the litigation from the first consumer claims through multi-district consolidation, settlements, and appeals. Every entry is footnoted with links to peer-reviewed journals, FDA announcements, and court documents. For those exploring their own legal options, we offer educational overviews of statute-of-limitations rules, damage categories, and the distinction between class actions and individual lawsuits. Our goal is to demystify the process so that readers can make informed decisions—without ever promising outcomes or soliciting clients.
Timeline of Zantac (Ranitidine) NDMA Contamination
One of our most visited resources is the interactive timeline that tracks the Zantac story from its 1983 FDA approval through the 2019 discovery of NDMA instability, the subsequent recalls, and the ongoing scientific debate about risk at therapeutic doses. We update this timeline quarterly as new research emerges or court rulings are issued. Alongside the chronology, we provide educational sidebars explaining key concepts: acceptable daily intake limits, the Ames test for mutagenicity, and the pharmacokinetics of ranitidine under different storage conditions. This section is designed for anyone who wants a bird’s-eye view of a complex, decades-spanning controversy.
Educational Scope: Understanding Legal and Medical Contexts
The Stephan Beck Archive takes a deliberately interdisciplinary approach. A single lawsuit over an allegedly carcinogenic drug touches on analytic chemistry, regulatory law, toxicology, epidemiology, and civil procedure. Our articles bridge these fields, offering—for example—a primer on how the “learned intermediary” doctrine applies to over-the-counter medications, alongside a explainer on the difference between genotoxic and non-genotoxic carcinogens. We also host a series of guest essays from medical historians who place the Zantac affair in the broader context of past drug-safety scandals (thalidomide, Vioxx) and the evolution of the FDA’s risk-evaluation framework.
For an in-depth look at the legal landscape surrounding ranitidine, explore our featured guide: Zantac Cancer Lawsuit Claims: Legal Information and Case Evaluation Guidance. That page synthesizes the key scientific findings, explains how current claims are evaluated by courts and settlement trusts, and provides a step-by-step overview of what individuals should expect if they are considering legal action. Like everything on this site, it is written with an editorial, educational voice—accurate, impartial, and deeply sourced.
We invite you to browse the rest of our archive, where you will find similar depth on topics ranging from the history of H2-receptor antagonists to the global regulatory response to NDMA impurities. Our commitment is to maintain a living, breathing publication—updated regularly, free from commercial influence, and dedicated to the principle that an informed public is the best safeguard against future failures in drug safety. Thank you for trusting the Stephan Beck Archive as your resource.
That said, claimants should organize records, treatment chronology, and exposure evidence before legal intake. Compliance terms: FDA; statute of limitations; class action; MDL; mass tort; plaintiff; settlement; adverse event; litigation; compensation.